Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$159.69 USD
+0.16 (0.10%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $159.69 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$159.69 USD
+0.16 (0.10%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $159.69 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth F Momentum D VGM
Zacks News
The Zacks Analyst Blog Highlights: Johnson & Johnson, Wells Fargo, Wal-Mart, Kimberly-Clark and NIKE
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Wells Fargo, Wal-Mart, Kimberly-Clark and NIKE
AbbVie (ABBV) Presents Impressive Imbruvica Data at ASH
by Zacks Equity Research
AbbVie Inc. (ABBV) and partner Janssen, Johnson & Johnson's (JNJ) pharmaceuticals subsidiary, presented encouraging results on their cancer drug Imbruvica at the annual meeting of the American Society of Hematology.
Lilly: Jardiance Label to Add Cardiovascular Indication
by Zacks Equity Research
Eli Lilly & Company (LLY) recently announced that the FDA has approved the inclusion of cardiovascular (CV) risk reduction data from the EMPA-REG OUTCOME study on its type II diabetes drug Jardiance's (SGLT-2 inhibitor) label.
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Nxstage Medical
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Nxstage Medical
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Roche
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Roche
Achillion, J&J to Initiate Phase IIb Study on HCV Combo
by Zacks Equity Research
Achillion Pharmaceuticals, Inc. (ACHN) announced the initiation of patient dosing in a global phase IIb on JNJ-4178 ??? a triple combination of AL-335, odalasvir (also known as ACH-3102) and J&J's Olysio (simeprevir).
Pfizer's Herceptin Biosimilar Meets Primary Endpoint in Study
by Zacks Equity Research
Pfizer, Inc. (PFE) recently announced that its experimental biosimilar of Roche Holding AG's (RHHBY) breast cancer drug - Herceptin - has reached the primary endpoint in a pivotal study.
MedTech Industry Stock Outlook - December 2016
by Zacks Equity Research
The Republican win marked a great victory for the entire medical device industry as the likelihood of a permanent repeal of the 2.3% medical device excise tax will come as a big bonus.
J&J (JNJ) Stands Tall in 2016: Reasons for Outperformance
by Zacks Equity Research
Johnson & Johnson's (JNJ) share price is up 9.5% in the year-to-date period. This compares favorably with the 8.0% fall for the Zacks classified Large-Cap Pharma industry.
Stock Market News for November 28, 2016
by Zacks Equity Research
Company News for November 28, 2016
by Zacks Equity Research
Companies in the News are: JNJ,TAC,CTRP,NAVB,CAH
The Zacks Analyst Blog Highlights: Johnson & Johnson, Ascena Retail, Financial Sector, Industrials and Health care
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Ascena Retail, Financial Sector, Industrials and Health care
Trump Rotation Stocks to Buy Right Now
by David Bartosiak
The Trump Rotation has seen money flow into financials, healthcare and industrials but the opportunity is in retail
Stock Market News for November 08, 2016
by Zacks Equity Research
Benchmarks ended higher on Monday after the FBI said that it would not press criminal charges against Democratic nominee Hillary Clinton
The Zacks Analyst Blog Highlights: Johnson & Johnson, Wells Fargo, Facebook and Qualcomm
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Wells Fargo, Facebook and Qualcomm
Big Q3 Earnings Checklist, Plus Latest CPI
by Mark Vickery
We've got plenty of notable stocks reporting before the bell today, including many large financial institutions on Wall Street.
6 Healthcare Stocks Investors Cannot Miss in Q3 Earnings
by Zacks Equity Research
A number of healthcare companies are recording improvements in their financial numbers.
A Whole Lot of Nothing
by Sheraz Mian
Stocks haven't done much lately and the trend will likely continue for some time.
Is the Earnings Picture Improving?
by Sheraz Mian
There are some tell-tale signs of improvement in the aggregate earnings picture.
Is the Earnings Picture Improving?
by Sheraz Mian
There are some tell-tale signs of improvement in the aggregate earnings picture.
Stock Market News for July 20, 2016
by Zacks Equity Research
The Dow ended in the green for the eighth consecutive session on Tuesday following Johnson & Johnson's commendable quarterly performance
MedTech Industry Stock Outlook - July 2016
by Zacks Equity Research
Two full quarters of 2016 are behind us and, while we await second quarter results over the coming weeks, we hardly expect a change in trend in the bullish MedTech sector.
Stock Market News for June 03, 2016
by Zacks Equity Research
Benchmarks finished in the green on Thursday following encouraging U.S. private sector jobs data and gains in healthcare stocks
Hedge Funds Are Buying These Stocks, Should You?
by Jeremy Mullin
Following the smart money can lead to big gains.
Bear of the Day: AbbVie (ABBV)
by Kevin Cook
Estimates were already sliding before the Feds took up the patent fight by "hopeful rival" Coherus